KWC/H Knowlton Capital

Global Canna Labs successfully exports Medical Cannabis from Jamaica to Canada for scientific purposes as its intended use

Global Canna Labs successfully exports Medical Cannabis from Jamaica to Canada for scientific purposes as its intended use

MONTRÉAL, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Elixxer Ltd. (TSX-V: ELXR and OTC-QB: ELXIF) (“ELIXXER”) is pleased to announce that Global Canna Labs has successfully exported 10 kilograms of medical cannabis from Jamaica into Canada. 

Global Canna is one of the foremost medical cannabis companies in Jamaica. The company operates under a tier 3 operator’s license on its 270,000 square foot facility in the heart of Montego Bay. The tier 3 license is one of the largest issued Licensees by the CLA for the cultivation and production of medical cannabis.  

Orville Powell, Chief Operating Officer of Global Canna remarked, “The commercial export of cannabis flower from Jamaica to Canada was a very rigorous and challenging process but in the end we got it done and our team has a tremendous feeling of satisfaction.  The process took effort and coordination from a number of individuals and parties. Our team at Global Canna is extremely grateful for the outstanding professionalism shown by the , the Ministry of Agriculture, Customs and the folks at the airport.” 

Blessed with an ideal microclimate for economical, high-quality cannabis cultivation, Jamaica has a storied, world-famous association with the herb through reggae music and the Rastafarian faith. Global Canna plans to continue this cherished history by building Jamaican heritage cannabis brands that will become instant classics, globally.

“Global Canna worked for a significant amount of time behind the scenes to achieve our export goal. This benchmark cannabis export scientific purposes as the intended purpose  is very exciting for our company and Jamaica as a whole,” notes Paul Glavine, President of Global Canna. “The Company looks forward to additional shipments in Q4, 2019, to more international markets. The strains were a local 1:1 Jamaican indengious strain called jack hammer along with  wedding cake produced by world renowned Seed Junky Genetics.”

The CLA is presently working to finalize the export regulations for the industry which are expected before the end of this year.

Elixxer’s interest in Global Canna currently consists of (i) a significant investment of $2.5 million by way of a secured debenture, convertible into a 30% equity interest in Global Canna and (ii) a 5% royalty on Global Canna’s net sales.

About Elixxer Ltd. ()

Elixxer Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSX-V: ELXR) and the US OTC-QB exchange (OTCQB: ELXIF). It currently has investments in legal cannabis related  businesses in Australia, Jamaica, Switzerland, Italy, and Canada.

Credit: PuffPuffPost /global-canna-completes-first-commercial-quantity-export-to-canada/

For further information please contact:

President, John McMullen, ,

Caution Regarding Press Releases

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice Regarding Forward Looking Statements

This press release may contain forward-looking statements with respect to Elixxer and its operations, strategy, investments, financial performance and condition. These statements can generally be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of Elixxer could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under “Risk Factors and Risk Management” in Elixxer’s most recent Management’s Discussion and Analysis filed on SEDAR (). The cautionary statements qualify all forward-looking statements attributable to Elixxer and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release, and Elixxer has no obligation to update such statements, except to the extent required by applicable securities laws. 

EN
09/12/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Knowlton Capital

 PRESS RELEASE

Elixxer Ltd. Announces Amendment to Proposed Debt Settlement Transacti...

Elixxer Ltd. Announces Amendment to Proposed Debt Settlement Transactions MONTRÉAL, March 09, 2021 (GLOBE NEWSWIRE) -- Elixxer Ltd. (the “Corporation” or “Elixxer”) (TSX-V: ELXR and OTC-QB: ELIXF) wishes to announce that, in light of current market uncertainty and the further deterioration in the Corporation’s share price, the Corporation’s principal secured lender has requested that the debt settlement transactions announced on March 2, 2021 be effected at a price of $0.015 per share as opposed to the previously disclosed price of $0.02 per share. As a result of this amendment, $3,656,3...

 PRESS RELEASE

Elixxer Ltd. Announces Revised Debt Settlement Transactions

Elixxer Ltd. Announces Revised Debt Settlement Transactions MONTRÉAL, March 02, 2021 (GLOBE NEWSWIRE) -- Elixxer Ltd. (the “Corporation” or “Elixxer”) (TSX-V: ELXR and OTC-QB: ELIXF) announces revised terms of its proposed debt settlement transactions. The Corporation proposes to settle a total of $8,568,333 of debt owed by the Corporation through the issuance of securities. The debt to be settled includes $3,964,826, including interest and fees, owed to AIP Convertible Private Debt Fund LP (“AIP”) pursuant to a loan agreement dated November 8, 2019 (the “AIP Debt”). The Corporation prop...

 PRESS RELEASE

Elixxer Ltd. Provides Corporate Update

Elixxer Ltd. Provides Corporate Update MONTRÉAL, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Elixxer Ltd. (TSX-V: ELXR) (OTC-QB: ELIXF) (FRA: 2LQA) (“Elixxer” or (the “Company”) wishes to announce that it has been in discussions with YA II PN, Ltd. and Riverfort Global Opportunities PLC (the “Lenders”) over claims that Elixxer is in default under the terms of its previously announced convertible loan agreement with the Lenders (see press release dated March 17, 2020). Negotiations towards arriving at a resolution are ongoing; however, if such negotiations prove to be unsuccessful, it may result in ...

 PRESS RELEASE

Little Green Pharma selected to supply France’s medical cannabis pilot...

Little Green Pharma selected to supply France’s medical cannabis pilot program MONTRÉAL, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Elixxer Ltd. (TSX-V: ELXR) (OTC-QB: ELIXF) (FRA: 2LQA) (“Elixxer” or the “company”) is pleased to share the latest achievements of its largest holding Little Green Pharma Ltd. (LGP). LGP has achieved the following major milestone validating our investment: The French Agency for the Safety of Medicines and Health Products (ANSM) has selected Little Green Pharma as 1 of 4 companies that will supply France’s medical cannabis pilot program. Under the program, participant...

 PRESS RELEASE

Elixxer Ltd. Announces Change in CEO

Elixxer Ltd. Announces Change in CEO MONTRÉAL, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Elixxer Ltd. (TSX-V: ELXR) (OTC-QB: ELIXF) (FRA: 2LQA) (“Elixxer” or (the “Company) announces that, effective immediately, Mazen Haddad has ceased to be the Company’s Chief Executive Officer. Mr. Haddad continues to serve as a non-executive director of the Company. The Board of Directors has named Mr. Ferras Zalt, the Company’s Chairman, to serve as the Interim Chief Executive Officer of Elixxer. About Elixxer Ltd. () Elixxer is a Canadian public company listed on the TSX Venture Exchange (TSX-V: ELXR) and...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch